Administration of raloxifene does not influence 24-hour ambulatory blood pressure of postmenopausal women with osteopenia: A double-blind placebo-controlled study

American Journal of Obstetrics and Gynecology

Volumn 188, Issue 5, 2003, Pages 1278-1282

  Cagnacci, Angelo ^a   Zanni, Anna Lisa ^a   Volpe, Annibale ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Blood pressure; Cardiovascular disease; Menopause; Raloxifene

Indexed keywords

FOLLITROPIN; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HEART RATE VARIABILITY; HUMAN; LONG TERM CARE; OSTEOPENIA; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SYSTOLIC BLOOD PRESSURE;

EID: 0038733994     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2003.299     Document Type: Article

References (25)

1. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997;277:1508-10.
2. Bryant HU, Glasebrook AL, Yang NN, Sato M. An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol 1999;69:37-44.
3. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from MORE randomized trial: multiple outcome of raloxifene evaluation. JAMA 1999;281:2189-97.
4. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997;96:1964-9.
5. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
6. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, et al. The effect of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 2000;85:214-8.
7. Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F, et al. Randomized, double-bind, placebo controlled study on the effects of raloxifene and hormone replacement therapy on plasma nitric oxide concentrations, endothelin-1 levels and endothelium-dependent vasodilatation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001;21:1512-9.
8. de Valk-de Roo GW, Stehouwer CD, Meijer P, Mijatovic V, Kluft C, Kenemans P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999;19:2993-3000.
9. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the USA adult population: results from the Third National Health and Nutrition Examination Survey: 1988-1991. Hypertension 1995;25:305-13.
10. Steassen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens 1989;3:427-33.
11. van Beresteyn EC, vont Hof MA, De Waard H. Contributions of ovarian failure and aging to blood pressure in normotensive perimenopausal women: a mixed longitudinal study. Am J Epidemiol 1989;129:947-55.
12. Sorensen MB, Rasmussen V, Jensen G, Ottesen B. Temporal changes in clinic and ambulatory blood pressure during cyclic post-menopausal hormone replacement therapy. J Hypertens 2000;18:1387-91.
13. Akkad AA, Halligan AW, Abrams K, Al-Azzawi F. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstet Gynecol 1997;89:97-103.
14. Cagnacci A, Rovati L, Zanni AL, Malmusi S, Facchinetti F, Volpe A. Physiological doses of estradiol decrease nocturnal blood pressure in normotensive postmenopausal women. Am J Physiol 1999;276:H1355-60.
15. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999;33:1190-4.
16. Vongpatanasin W, Tuncel M, Mansour Y, Arbique D, Victor RG. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 2001;103:2903-8.
17. Harvey PJ, Molloy D, Upton J, Wing LM. Dose response effect of conjugated equine estrogen on blood pressure in postmenopausal women with hypertension. Blood Press 2000;9:275-82.
18. Mercuro G, Zoncu S, Piano D, Pilia I, Iao A, Melis GB, et al. Estradiol-17beta reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am J Hypertens 1998;11:909-13.
19. Szekacs B, Vajo Z, Acs N, Hada P, Csuzi L, Bezeredi J, et al. Hormone replacement therapy reduces mean 24-h blood pressure and its variability in postmenopausal women with treated hypertension. Menopause 2000;7:31-5.
20. Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000;35:844-51.
21. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:721-6.
22. Cerquetani E, Mercuro G, Fini M, Zoncu S, Onorati D, Vitale C, et al. Hormone replacement therapy but not raloxifene improves endothelial function in postmenopausal women with increased cardiovascular risk [abstract]. Menopause 2001;8:453.
23. Cagnacci A, Arangino S, Renzi A, Zanni AL, Volpe A. Raloxifene does not influence flow-mediated endothelium-dependent and endothelium-independent vasodilatation of osteopenic postmenopausal women. Am J Obstet Gynecol 2003;188:313-7.
24. Cagnacci A, Paoletti AM, Zanni AL, Arangino S, Ibba G, Orrù M, et al. Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women. J Clin Endocrinol Metab 2002;87:4117-21.
25. Barrett-Connor E, Sashegyi A, Anderson PA, Cox DA, Hoszowski K, Harper KD, for the MORE Investigators. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.